Investors
Information Disclosure
-
CONNECTED TRANSACTION IN RELATION TO (1) ACQUISITION OF 29.99% EQUITY INTEREST IN THE TARGET COMPANY; AND (2) POSSIBLE VOLUNTARY PARTIAL OFFER TO ACQUIRE A MAXIMUM OF 25.01% EQUITY INTEREST IN THE TARGET COMPANY2024.10.30
-
VOLUNTARY DISCLOSURE - 2024 THIRD QUARTER UPDATE2024.10.30
-
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW INDICATION APPLICATION FOR MARKETING OF ANLOTINIB HYDROCHLORIDE CAPSULES IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA2024.10.21
-
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY CHIA TAI TIANQING UNDER THE SHARE INCENTIVE SCHEME2024.10.21
-
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY CHIA TAI TIANQING UNDER THE SHARE INCENTIVE SCHEME2024.10.09
-
VOLUNTARY ANNOUNCEMENT - SIGNING OF AN EXCLUSIVE LICENSE AND COOPERATION AGREEMENT WITH YZY BIOPHARMA2024.10.08
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2024.10.07
-
VOLUNTARY ANNOUNCEMENT - PROGRESS UPDATE ON THE "IMPLEMENTATION OF SHARE INCENTIVE SCHEME BY CHIA TAI TIANQING"2024.10.04